MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

United Therapeutics Corp

Slēgts

SektorsVeselības aprūpe

295.8 0.9

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

289.05

Max

297.62

Galvenie mērījumi

By Trading Economics

Ienākumi

-7.8M

301M

Pārdošana

-13M

736M

P/E

Sektora vidējais

11.884

57.333

EPS

6.19

Peļņas marža

40.943

Darbinieki

1,305

EBITDA

6.3M

424M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+29.27% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 30. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-3.4B

13B

Iepriekšējā atvēršanas cena

294.9

Iepriekšējā slēgšanas cena

295.8

Tehniskais rādītājs

By Trading Central

Pārliecība

Very Strong Bullish Evidence

United Therapeutics Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2024. g. 7. okt. 15:14 UTC

Galvenie tirgus virzītāji

Liquidia Shares Rise After Supreme Court Rejects United Therapeutics' Patent Appeal

2025. g. 28. janv. 10:30 UTC

Top Ziņas

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

Salīdzinājums

Cenas izmaiņa

United Therapeutics Corp Prognoze

Cenas mērķis

By TipRanks

29.27% augšup

Prognoze 12 mēnešiem

Vidējais 383.18 USD  29.27%

Augstākais 460 USD

Zemākais 293 USD

Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi United Therapeutics Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

11 ratings

8

Pirkt

3

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

285.09 / 298.295Atbalsts un pretestība

Īstermiņā

Very Strong Bullish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.